This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A new immunologic model for the induction and persistence of leukemia or lymphoma in mice may change classification, differential diagnosis, and therapy for certain animal and human leukemias and lymphomas.
What's more, contends James N. Ihle, PhD, of the Litton Bionetics-National Cancer Institute's Frederick Cancer Research Facility in Frederick, Md, cyclosporine conceivably may play a role in therapy.
Ihle, who discussed his work at the recent international symposium of the International Association for Comparative Research on Leukemia and Related Diseases in Cambridge, England, believes he has found a specific lymphokine—a regulatory protein secreted by lymphocytes—necessary for the formation, growth, and survival of lymphomas in a strain (BALB/c) of mice. Not only do the malignant cells carry receptors for this lymphokine, but their growth is dependent on its presence.
The lymphokine is interleukin 3 (IL-3), one of many lymphokines produced when helper T cells are stimulated by (among other things) antigens on the
Ziporyn T. Cyclosporine may inhibit mouse lymphoma growth. JAMA. 1983;250(22):3023–3024. doi:10.1001/jama.1983.03340220007004
Customize your JAMA Network experience by selecting one or more topics from the list below.